We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

CAROLINA LIQUID CHEMISTRIES

Carolina Liquid Chemistries offers a complete line of clinical chemistry analyzers and reagents for use on common pla... read more Featured Products: More products

Download Mobile App




Automated Glycated Hemoglobin Assay Now Certified by US Glycohemoglobin Standardization Program

By LabMedica International staff writers
Posted on 24 Jul 2014
An assay for the measurement of glycated hemoglobin (HbA1c) designed for use on a new-generation automated chemistry analyzer was recently certified by the [US] National Glycohemoglobin Standardization Program (NGSP).

HbA1c is a derivative of hemoglobin that is formed nonenzymically by reaction at the N terminus of the protein molecule with glucose. More...
In the normal adult human such derivatives constitute a few percent of the total erythrocyte hemoglobin, the most abundant being hemoglobin A1c, which increases several fold in concentration in diabetes mellitus, and is assayed to monitor control of diabetes. Once a hemoglobin molecule is glycated, it remains that way. A buildup of glycated hemoglobin within the red cell, therefore, reflects the average level of glucose to which the cell has been exposed during its life-cycle. Measuring glycated hemoglobin assesses the effectiveness of therapy by monitoring long-term serum glucose regulation. The HbA1c level is proportional to average blood glucose concentration over the previous four weeks to three months.

In the United States, HbA1c testing laboratories are certified by the National Glycohemoglobin Standardization Program (NGSP) to standardize them against the results of the 1993 Diabetes Control and Complications Trial (DCCT). This landmark study showed that the risk for development and progression of the chronic complications of diabetes was closely related to the degree of glycemic control, as measured by HbA1c. The DCCT also provided a large body of data relating HbA1c values to mean blood glucose.

Carolina Liquid Chemistries Corporation (Winston-Salem, NC, USA) recently announced today that its new Hemoglobin A1c test (HbA1c-direct), designed for use on the CLC720 chemistry analyzer had been certified by the NGSP.

“There are other HbA1c tests on the market,” said Patricia Shugart, chief operating officer at Carolina Liquid Chemistries Corporation, “but our HbA1c-direct is special in two ways. First, it’s a direct test, meaning there is no manual sample pretreatment. Second, it is categorized as moderately complex, which avoids the extra cost of a high complexity lab.”

The speed and ease of HbA1c-direct is made possible by the enhanced capabilities of the CLC720 chemistry analyzer, which, unlike most analyzers in its class, automates the lysing step that would otherwise have to be performed manually.

“Our test correlates to the NGSP certified tests used in large-scale diabetes studies,” said Patricia Shugart. “Physicians can now relate their HbA1c-direct results to these studies, providing more relevance.”

Related Links:
Carolina Liquid Chemistries Corporation




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.